BIO’s own David Thomas, Director of Industry Research, delivered opening remarks at the BIO-Europe Spring conference in Barcelona yesterday. His slides provide a snapshot of the biotech industry’s performance and highlight emerging trends in venture exits: IPOs and M&A.
Takeaways from his talk include breakouts on multiple fronts for the industry:
- FDA approvals at highs not seen since the 1990s
- Orphan designation approvals at all-time highs
- IPOs starting to show signs of life in 2012 and 2013
- Highest level of structured acquisitions in 2012
- Highest number of corporate venture rounds on record for 2012
- Venture returns trending up in 2012
Download the full slide deck here: BES13 – David Thomas Slides
